文献速递皮肤肿瘤

女性默克尔细胞癌患者生存优于男性

Improved survival in women versus men with merkel cell carcinoma.
PubMed 文献 · J Am Acad Dermatol · 2020-05-15

基于NCDB和SEER数据库,纳入接受手术及淋巴结评估的非转移性默克尔细胞癌患者,比较男女生存差异。倾向评分匹配后女性5年总生存率66.0% vs 男性56.8%(P<.001),多变量Cox风险比0.68(95%CI 0.61-0.75)。SEER验证队列显示女性生存优势完全源于MCC特异性死亡率差异(5年累积发生率16.4% vs 26.7%,P=.002),其他原因死亡率无差异。

要点

  • 女性MCC患者总生存优于男性,多变量校正后HR 0.68。
  • 生存优势由MCC特异性死亡率驱动,非其他原因死亡。
  • SEER验证队列中女性5年MCC特异性累积死亡率16.4% vs 男性26.7%。

核心结论

  • 在默克尔细胞癌中,女性生存优于男性,该优势由MCC相关死亡率差异驱动。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库(NCDB)和SEER数据库。
  • NCDB队列纳入4178例接受手术和淋巴结评估的非转移性MCC患者,其中女性1516例(36%)。
  • SEER验证队列纳入1202例,其中女性457例(38.0%)。
  • 采用Kaplan-Meier分析和Cox比例风险回归分析总生存,竞争风险分析和Fine-Gray模型分析病因特异性及其他原因死亡。

主要发现

  • 倾向评分匹配后,女性5年总生存率66.0%,男性56.8%(P<.001)。
  • 多变量Cox回归显示女性死亡风险低于男性(HR 0.68,95%CI 0.61-0.75,P<.001)。
  • SEER验证队列中,女性5年MCC特异性累积死亡率为16.4%,男性为26.7%(P=.002)。
  • 倾向评分匹配患者中,其他原因死亡率女性16.8% vs 男性17.8%(P=.43),无显著差异。

临床怎么用

  • 临床评估MCC预后时应考虑性别差异,女性预后相对较好。
  • 男性MCC患者可能需要更密切的随访或更积极的治疗策略。

局限性

  • 回顾性数据集可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies have observed that women have better outcomes than men in melanoma, but less is known about the influence of sex differences on outcomes for other aggressive cutaneous malignancies. OBJECTIVE: To investigate whether women and men have disparate outcomes in Merkel cell carcinoma (MCC). METHODS: Patients with nonmetastatic MCC undergoing surgery and lymph node evaluation were identified from the National Cancer Database (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier analysis and Cox proportional hazards regression models were used for overall survival, and competing-risks analysis and Fine-Gray models were used for cause-specific and other-cause mortality. RESULTS: The NCDB cohort (n = 4178) included 1516 (36%) women. Women had a consistent survival advantage compared with men in propensity score-matched analysis (66.0% vs 56.8% at 5 years, P < .001) and multivariable Cox regression (hazard ratio, 0.68; 95% confidence interval, 0.61-0.75; P < .001). Similarly, women had a survival advantage in the SEER validation cohort (n = 1202) with 457 (38.0%) women, which was entirely due to differences in MCC-specific mortality (5-year cumulative incidence: 16.4% vs 26.7%, P = .002), with no difference in other-cause mortality (16.8% vs 17.8%, P = .43) observed in propensity score-matched patients. LIMITATIONS: Potential selection bias from a retrospective data set. CONCLUSION: In MCC, women have improved survival compared with men, driven by MCC-related mortality.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Tam M, Luu M, Barker CA, et al. Improved survival in women versus men with merkel cell carcinoma. J Am Acad Dermatol. 2020. PMID: 32423829. doi:10.1016/j.jaad.2020.02.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。